Fatty Liver Clinical Trials

As a patient at Cedars-Sinai, you will have access to the latest clinical trials and research for fatty liver. Backed by a respected team of specialists and researchers, our clinical trials aim to further the advancement of diagnosing and treating your fatty liver condition.

Questions? See the Clinical Trials FAQs.


Click below to view clinical trials by areas:

Liver Cirrhosis

Condition:

Nonalcoholic fatty liver disease, cirrhosis, hepatocellular carcinoma

Key Inclusion Criteria:

  • At least 18 years old
  • History of nonalcoholic fatty liver disease with or without cirrhosis or hepatocellular carcinoma diagnosed within the last 6 months

Summary:

This study focuses on patients from Cedars-Sinai and Veteran's Administration Greater Los Angeles Healthcare System who have liver disease. Researchers believe that differences in gut bacteria and the products of these bacteria, together with other factors such as diet and body composition, may help to explain why some people with nonalcoholic liver disease progress to liver cirrhosis or cancer. In this study, researchers will evaluate the differences between biomarkers measured in participants' specimens, clinical data, and questionnaire data to learn more about why nonalcoholic fatty liver disease progresses in some people.

Nonalcoholic Steatohepatitis (NASH)

Condition:

Nonalcoholic steatohepatitis

Key Inclusion Criteria:

  • 18-75 years old
  • Groups 1-6:
    • Diagnosis of nonalcoholic fatty liver disease
    • Screening FibroTest <0.75
    • Screening magnetic resonance imaging-proton density fat fraction (MRI-PDFF) with ≥10% steatosis
    • Screening magnetic resonance elastography (MRE) with liver stiffness ≥2.88 kPa, or
    • Historical liver biopsy consistent with NASH with stage 2-3 fibrosis, and
    • No documented weight loss >5% between the date of the liver biopsy and screening

Summary:

The purpose of this study is to evaluate the experimental drugs selonsertib (SEL; formerly GS-4997), GS-0976 and GS-9674 for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a disease that results when fat accumulates in the liver. The body’s immune system may respond to the fat by attacking liver cells and over time, scar tissue (fibrosis) forms. SEL, GS-0976 and GS-9674 are intended to reduce inflammation, fibrosis, and fat buildup in the liver. Researchers will assess the safety, tolerability and effectiveness of these drugs in NASH patients.

Condition:

Nonalcoholic Steatohepatitis

Key Inclusion Criteria:

  • 18-75 years old
  • Confirmation of steatohepatitis on a diagnostic liver biopsy
  • Fibrosis Stage 1 or greater and below Stage 4 (according to the NASH Clinical Research Network fibrosis staging system)
  • Body mass index ≤45 kg/m²

Summary:

This study focuses on patients diagnosed with nonalcoholic steatohepatitis (NASH) with fibrosis (recently confirmed by a liver biopsy) or those who are at high risk of having this disease and are willing to undergo a liver biopsy to determine whether they have NASH with fibrosis. The purpose of the study is to evaluate the safety and effectiveness of an investigational drug called elafibranor in these patients. Researchers will assess the efficacy of elafibranor compared to placebo (inactive substance) for the treatment of NASH. The study will also evaluate whether elafibranor reduces the number of patients that will develop further complications from NASH, such as liver cirrhosis.

Condition:

Nonalcoholic steatohepatitis

Key Inclusion Criteria:

  • Liver biopsy consistent with NASH and bridging (F3 fibrosis)
  • Meets specific laboratory parameters at the screening visit

Summary:

This study focuses on patients who have advanced liver fibrosis without cirrhosis as a result of nonalcoholic steatohepatitis (NASH). The study will test an experimental drug called selonsertib for the treatment of advanced liver fibrosis due to NASH. NASH is a disease that results when fat accumulates in the liver; the body’s immune system may respond by attacking the liver cells. Selonsertib is being developed to reduce inflammation and fibrosis in the liver. Researchers will assess the effects, safety and tolerability of selonsertib , as well as whether it can reduce fibrosis and associated complications in patients with cirrhosis and fibrosis due to NASH.

Condition:

Nonalcoholic steatohepatitis

Key Inclusion Criteria:

  • Liver biopsy consistent with NASH and cirrhosis
  • Meets specific laboratory parameters at the screening visit
  • Males and non-pregnant, non-lactating females between 18-70 years old

Summary:

This study focuses on patients who have liver cirrhosis as a result of nonalcoholic steatohepatitis (NASH). The study will evaluate an experimental drug called selonsertib for the treatment of advanced fibrosis of the liver due to NASH. NASH is a disease that results when fat accumulates in the liver; the body’s immune system may respond to the fat by attacking liver cells. Selonsertib is being developed to reduce inflammation and fibrosis in the liver. Researchers will assess the effects, safety and tolerability of selonsertib , as well as whether it can reduce fibrosis and associated complications in patients with cirrhosis and fibrosis due to NASH.